Business
HLS Therapeutics Provides Investor Update on the Canadian Launch of Vascepa® (Icosapent Ethyl)
HLS Therapeutics Provides Investor Update on the Canadian Launch of Vascepa® (Icosape...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nHLS Therapeutics Provides Investor Update on the Canadian Launch of Vascepa® (Icosapent Ethyl)\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, Jan. 28, 2020\n\n\n\nVascepa to be available on or about February 18, 2020, supported by a national Cardiovascular salesforce Vascepa becomes the first and only Health Canada-approved medication for reducing cardiovascular risk beyond cholesterol-lowering therapy in the studied high-risk patients approved for treatment Vascepa is supported by data from the REDUCE-IT® trial, an international 8,179 patient outcomes study that showed a 25% placebo-controlled risk reduction in the first occurrence of major adverse cardiovascular events Cardiovascular disease is the number one killer globally1 and HLS is taking steps to make Vascepa accessible and affordable to the Canadian population TORONTO, Jan. 28, 2020 /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, is pleased to update investors that Vascepa® (icosapent ethyl, or \"IPE\") will become available to Canadians on or about February 18, 2020. At launch, Vascepa will be supported by the Company's national Cardiovascular salesforce, initially sized at 22 representatives, in addition to eight other field-based roles.\nOn December 31, 2019, Vascepa was approved by Health Canada and is indicated to reduce the risk of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with elevated triglycerides who are at high risk of cardiovascular events due to established cardiovascular disease or diabetes and at least one other cardiovascular risk factor. \nVascepa was granted a Priority Review as it met Health Canada's criteria of intending to address a serious, life-threatening or debilitating disease or condition for which no drug was marketed in Canada, and for which there is substantial ev...